Rino Rappuoli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6619548/publications.pdf

Version: 2024-02-01

636 papers	62,587 citations	588 125 h-index	1629 215 g-index
659 all docs	659 docs citations	659 times ranked	39359 citing authors

#	Article	IF	Citations
1	Innovative vaccine approachesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1511, 59-86.	1.8	5
2	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
3	Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. Nature Immunology, 2022, 23, 275-286.	7.0	95
4	The trillion dollar vaccine gap. Science Translational Medicine, 2022, 14, eabn4342.	5.8	14
5	Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection. Nature Communications, 2022, 13, 2263.	5.8	6
6	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120976119.	3.3	27
7	Immune response in COVID-19: what is next?. Cell Death and Differentiation, 2022, 29, 1107-1122.	5.0	69
8	Reply to: HultstrÃ¶m et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Mannose-binding lectin genetics in COVID-19. Nature Immunology, 2022, 23, 865-867.	7.0	4
9	Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. Nature Communications, 2022, 13, .	5.8	20
10	Rapid generation of Shigella flexneri GMMA displaying natural or new and cross-reactive O-Antigens. Npj Vaccines, 2022, 7, .	2.9	2
11	4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-SerogroupÂB Meningococcal Strains in Adolescents. Infectious Diseases and Therapy, 2021, 10, 307-316.	1.8	17
12	Antibodies, epicenter of SARS-CoV-2 immunology. Cell Death and Differentiation, 2021, 28, 821-824.	5.0	9
13	Vaccinology in the postâ"COVID-19 era. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	62
14	The role of vaccines in combatting antimicrobial resistance. Nature Reviews Microbiology, 2021, 19, 287-302.	13.6	233
15	Immunodominant antibody germlines in COVID-19. Journal of Experimental Medicine, 2021, 218, .	4.2	27
16	Bacteriophages, a multi-tool to fight infectious disease. Med, 2021, 2, 209-210.	2.2	2
17	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature, 2021, 594, 253-258.	13.7	253
18	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell, 2021, 184, 1821-1835.e16.	13.5	180

#	Article	IF	Citations
19	The respiratory syncytial virus (RSV) prefusion Fâ€protein functional antibody repertoire in adult healthy donors. EMBO Molecular Medicine, 2021, 13, e14035.	3.3	14
20	SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. Nature Medicine, 2021, 27, 759-761.	15.2	65
21	Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension. Frontiers in Immunology, 2021, 12, 671325.	2.2	29
22	Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. Journal of Infection, 2021, 83, 17-26.	1.7	26
23	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	251
24	Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. EClinicalMedicine, 2021, 39, 101076.	3.2	37
25	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	13.5	131
26	Recent advances in the prevention of meningococcal B disease: Real evidence from 4CMenB vaccination. Vacunas (English Edition), 2021, 22, 189-202.	0.3	0
27	Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes. PLoS Neglected Tropical Diseases, 2021, 15, e0009826.	1.3	10
28	Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature, 2021, 600, 530-535.	13.7	124
29	Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect. Npj Vaccines, 2021, 6, 130.	2.9	24
30	Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents. Pediatric Infectious Disease Journal, 2021, 40, e66-e71.	1.1	7
31	Vaccines 2020: The era of the digital vaccine is here. Science Translational Medicine, 2021, 13, eabm3249.	5.8	13
32	Vaccine innovations for emerging infectious diseasesâ€"a symposium report. Annals of the New York Academy of Sciences, 2020, 1462, 14-26.	1.8	15
33	Vaccines to Overcome Antibiotic Resistance: The Challenge of Burkholderia cenocepacia. Trends in Microbiology, 2020, 28, 315-326.	3.5	21
34	Timeline: Vaccines. Cell, 2020, 183, 552.	13.5	4
35	Vaccines against Meningococcal Diseases. Microorganisms, 2020, 8, 1521.	1.6	82
36	Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity. Nature Communications, 2020, 11, 4994.	5.8	4

#	Article	IF	Citations
37	Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus. International Journal of Molecular Sciences, 2020, 21, 8558.	1.8	26
38	Editorial overview: Vaccines 2020. Current Opinion in Immunology, 2020, 65, iii.	2.4	2
39	Vaccines as remedy for antimicrobial resistance and emerging infections. Current Opinion in Immunology, 2020, 65, 102-106.	2.4	11
40	Transforming vaccine development. Seminars in Immunology, 2020, 50, 101413.	2.7	35
41	Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM₁₉₇conjugate vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24443-24449.	3.3	24
42	Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine, 2020, 38, 7542-7550.	1.7	25
43	Structure of a protective epitope reveals the importance of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29795-29802.	3.3	19
44	Editorial: Advanced Immunization Technologies for Next Generation Vaccines. Frontiers in Immunology, 2020, 11, 878.	2.2	3
45	Vaccines Against Antimicrobial Resistance. Frontiers in Immunology, 2020, 11, 1048.	2.2	76
46	Drugs and Vaccines Will Be Necessary to Control Tuberculosis. Applied Sciences (Switzerland), 2020, 10, 4026.	1.3	1
47	Meningococcal factor H binding protein as immune evasion factor and vaccine antigen. FEBS Letters, 2020, 594, 2657-2669.	1.3	14
48	Development of vaccines at the time of COVID-19. MicroLife, 2020, 1, uqaa003.	1.0	4
49	4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp. PLoS Pathogens, 2020, 16, e1008882.	2.1	6
50	Vaccinology â€“ Editorial. Seminars in Immunology, 2020, 50, 101439.	2.7	1
51	Vaccine Evolution and Its Application to Fight Modern Threats. Frontiers in Immunology, 2019, 10, 1722.	2.2	32
52	Vaccines and global health: In search of a sustainable model for vaccine development and delivery. Science Translational Medicine, 2019, 11, .	5.8	88
53	Editorial: A Global Perspective on Vaccines: Priorities, Challenges and Online Information. Frontiers in Immunology, 2019, 10, 2556.	2.2	4
54	Long noncoding RNAs are involved in multiple immunological pathways in response to vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17121-17126.	3.3	58

#	Article	IF	Citations
55	Human monoclonal antibodies for discovery, therapy, and vaccine acceleration. Current Opinion in Immunology, 2019, 59, 130-134.	2.4	12
56	Inhibiting neuraminidase can make the difference. Journal of Experimental Medicine, 2019, 216, 251-252.	4.2	1
57	Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine, 2019, 37, 991-1000.	1.7	64
58	Comparison of Open-Source Reverse Vaccinology Programs for Bacterial Vaccine Antigen Discovery. Frontiers in Immunology, 2019, 10, 113.	2.2	107
59	Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction. Trends in Parasitology, 2019, 35, 483-486.	1.5	31
60	Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. Vaccine, 2019, 37, 3006-3021.	1.7	72
61	Self-Assembling Nanoparticles Usher in a New Era of Vaccine Design. Cell, 2019, 176, 1245-1247.	13.5	24
62	Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types. Expert Review of Vaccines, 2019, 18, 309-322.	2.0	15
63	Editorial: Reverse Vaccinology. Frontiers in Immunology, 2019, 10, 2776.	2.2	77
64	On the mechanisms of conjugate vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14-16.	3.3	96
65	Vaccines: An achievement of civilization, a human right, our health insurance for the future. Journal of Experimental Medicine, 2019, 216, 7-9.	4.2	27
66	Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. Scientific Reports, 2018, 8, 3700.	1.6	42
67	Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Review of Vaccines, 2018, 17, 1111-1121.	2.0	60
68	Vaccine candidates for poor nations are going to waste. Nature, 2018, 564, 337-339.	13.7	23
69	Technologies to address antimicrobial resistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12887-12895.	3.3	140
70	Antimicrobial resistance and the role of vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12868-12871.	3.3	120
71	Vision for a systems architecture to integrate and transform population health. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12595-12602.	3.3	9
72	Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10428-10433.	3.3	84

#	Article	IF	Citations
73	Glycoconjugate vaccines: Principles and mechanisms. Science Translational Medicine, 2018, 10, .	5.8	158
74	Sustainable vaccine development: a vaccine manufacturer's perspective. Current Opinion in Immunology, 2018, 53, 111-118.	2.4	22
75	Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Seminars in Immunology, 2018, 39, 14-21.	2.7	455
76	Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. The Lancet Gastroenterology and Hepatology, 2018, 3, 698-707.	3.7	69
77	Short-term and mid-term solutions for influenza vaccines. Lancet Infectious Diseases, The, 2018, 18, 832-833.	4.6	1
78	Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top. Frontiers in Immunology, 2018, 9, 1068.	2.2	179
79	Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines. Molecules, 2018, 23, 1340.	1.7	47
80	Farewell Stan Stanley Falkow: 1934â€“2018. Environmental Microbiology, 2018, 20, 2322-2333.	1.8	0
81	Core values for vaccine evaluation. Vaccine, 2017, 35, A57-A62.	1.7	9
82	Introduction to the vaccine supplement. Vaccine, 2017, 35, A1.	1.7	0
83	Emerging infectious diseases: A proactive approach. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4055-4059.	3.3	133
84	Structure of a protective epitope of group BStreptococcustype III capsular polysaccharide. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 5017-5022.	3.3	55
85	Editorial overview: Preventive and therapeutic vaccines: Vaccination against viral disease â€" current advances and challenges. Current Opinion in Virology, 2017, 23, vi-viii.	2.6	1
86	An unwanted guest:Neisseria meningitidisâ€“ carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence. Expert Review of Anti-Infective Therapy, 2017, 15, 689-701.	2.0	11
87	Emerging experience with meningococcal serogroup B protein vaccines. Expert Review of Vaccines, 2017, 16, 433-451.	2.0	54
88	Beyond cost-effectiveness: Using systems analysis for infectious disease preparedness. Vaccine, 2017, 35, A46-A49.	1.7	13
89	Improving accountability in vaccine decision-making. Expert Review of Vaccines, 2017, 16, 1057-1066.	2.0	9
90	Towards a more comprehensive approach for a total economic assessment of vaccines?. Journal of Market Access & Health Policy, 2017, 5, 1335162.	0.8	16

#	Article	IF	Citations
91	3. How comprehensive can we be in the economic assessment of vaccines?. Journal of Market Access & Health Policy, 2017, 5, 1336044.	0.8	8
92	Deploy vaccines to fight superbugs. Nature, 2017, 552, 165-167.	13.7	100
93	2. How is the economic assessment of vaccines performed today?. Journal of Market Access & Health Policy, 2017, 5, 1335163.	0.8	10
94	Compare voting systems to improve them. Nature, 2017, 541, 151-153.	13.7	7
95	Auto-Assembling Detoxified Staphylococcus aureus Alpha-Hemolysin Mimicking the Wild-Type Cytolytic Toxin. Vaccine Journal, 2016, 23, 442-450.	3.2	17
96	Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2714-2719.	3.3	73
97	Strategic Planning in Population Health and Public Health Practice: A Call to Action for Higher Education. Milbank Quarterly, 2016, 94, 109-125.	2.1	8
98	Vaccines for Staphylococcus aureus and Target Populations. Current Topics in Microbiology and Immunology, 2016, 409, 491-528.	0.7	36
99	Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Scientific Reports, 2016, 6, 29063.	1.6	45
100	Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. Journal of Experimental Medicine, 2016, 213, 469-481.	4.2	299
101	Editorial overview: Vaccines: novel technologies for vaccine development. Current Opinion in Immunology, 2016, 41, v-vii.	2.4	8
102	Multicriteria decision analysis and core values for enhancing vaccine-related decision-making. Science Translational Medicine, 2016, 8, 345ps14.	5.8	13
103	Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1853-1858.	3.3	176
104	Self-assembling protein nanoparticles in the design of vaccines. Computational and Structural Biotechnology Journal, 2016, 14, 58-68.	1.9	266
105	Staphylococcus aureus coagulase R domain, a new evasion mechanism and vaccine target. Journal of Experimental Medicine, 2016, 213, 292-292.	4.2	5
106	The role of structural proteomics in vaccine development: recent advances and future prospects. Expert Review of Proteomics, 2016, 13, 55-68.	1.3	27
107	One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A. PLoS ONE, 2016, 11, e0147767.	1.1	52
108	LytM Proteins Play a Crucial Role in Cell Separation, Outer Membrane Composition, and Pathogenesis in Nontypeable Haemophilus influenzae. MBio, 2015, 6, e02575.	1.8	42

#	Article	IF	Citations
109	Phagocyte subsets and lymphocyte clonal deletion behind ineffective immune response toStaphylococcus aureus. FEMS Microbiology Reviews, 2015, 39, 750-763.	3.9	40
110	Ebola vaccine R&D: Filling the knowledge gaps. Science Translational Medicine, 2015, 7, 317ps24.	5.8	41
111	Dual RNA-seq of Nontypeable Haemophilus influenzae and Host Cell Transcriptomes Reveals Novel Insights into Host-Pathogen Cross Talk. MBio, 2015, 6, e01765-15.	1.8	123
112	Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1767-1772.	3.3	129
113	Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Science Translational Medicine, 2015, 7, 294ra105.	5.8	206
114	Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines. Vaccine, 2015, 33, 3628-3635.	1.7	21
115	Sequence type 1 group B Streptococcus , an emerging cause of invasive disease in adults, evolves by small genetic changes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6431-6436.	3.3	81
116	Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3680-3685.	3.3	166
117	Developing vaccines for an aging population. Science Translational Medicine, 2015, 7, 281ps8.	5.8	21
118	Lessons from Reverse Vaccinology for viral vaccine design. Current Opinion in Virology, 2015, 11, 89-97.	2.6	33
119	Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination. Journal of Immunology, 2015, 195, 1617-1627.	0.4	64
120	The Human Pathogen Streptococcus pyogenes Releases Lipoproteins as Lipoprotein-rich Membrane Vesicles. Molecular and Cellular Proteomics, 2015, 14, 2138-2149.	2.5	51
121	Neisseria meningitidis: pathogenesis and immunity. Current Opinion in Microbiology, 2015, 23, 68-72.	2.3	104
122	Recognition of Neisseria meningitidis by the Long Pentraxin PTX3 and Its Role as an Endogenous Adjuvant. PLoS ONE, 2015, 10, e0120807.	1.1	29
123	Role of ARF6, Rab11 and External Hsp90 in the Trafficking and Recycling of Recombinant-Soluble Neisseria meningitidis Adhesin A (rNadA) in Human Epithelial Cells. PLoS ONE, 2014, 9, e110047.	1.1	16
124	Neisseria Adhesin A Variation and Revised Nomenclature Scheme. Vaccine Journal, 2014, 21, 966-971.	3.2	54
125	Bringing influenza vaccines into the 21st century. Human Vaccines and Immunotherapeutics, 2014, 10, 600-604.	1.4	14
126	Designing Vaccines for the Twenty-First Century Society. Frontiers in Immunology, 2014, 5, 12.	2.2	94

#	Article	IF	Citations
127	<scp>HCV E1E</scp>2â€<scp>MF</scp>59 vaccine in chronic hepatitis <scp>C</scp> patients treated with <scp>PEG</scp>â€<scp>IFN</scp>Î±2a and <scp>R</scp>ibavirin: a randomized controlled trial. Journal of Viral Hepatitis, 2014, 21, 458-465.	1.0	19
128	Vaccines, new opportunities for a new society. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12288-12293.	3.3	237
129	Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17128-17133.	3.3	60
130	Neisseria meningitidis NalP cleaves human complement C3, facilitating degradation of C3b and survival in human serum. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 427-432.	3.3	65
131	A priority-setting aid for new vaccine candidates. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3199-3200.	3.3	13
132	Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses. Journal of Virology, 2014, 88, 5502-5510.	1.5	59
133	Cost effectiveness has its place, but so does common sense. BMJ, The, 2014, 349, g6759-g6759.	3.0	4
134	Genome sequencing of disease and carriage isolates of nontypeable Haemophilus influenzae identifies discrete population structure. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5439-5444.	3.3	104
135	1885, the first rabies vaccination in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12273-12273.	3.3	21
136	Changing route: aerosol vaccine against tuberculosis. Lancet Infectious Diseases, The, 2014, 14, 901-902.	4.6	7
137	Vaccines: Science, health, longevity, and wealth. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12282-12282.	3.3	22
138	Vaccines for the 21st century. EMBO Molecular Medicine, 2014, 6, 708-720.	3.3	342
139	From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nature Reviews Immunology, 2014, 14, 505-514.	10.6	185
140	Vaccine adjuvants: the future is bright. Expert Review of Vaccines, 2013, 12, 727-729.	2.0	3
141	Correlates of protection against influenza infection in humansâ€"on the path to a universal vaccine?. Current Opinion in Immunology, 2013, 25, 470-476.	2.4	40
142	Auto ADPâ€ribosylation of NarE, a Neisseria meningitidis ADPâ€ribosyltransferase, regulates its catalytic activities. FASEB Journal, 2013, 27, 4723-4730.	0.2	9
143	Finding Epitopes with Computers. Chemistry and Biology, 2013, 20, 1205-1206.	6.2	4
144	Human circulating influenza-CD4 ⁺ ICOS1 ⁺ IL-21 ⁺ T cells expand after vaccination, exert helper function, and predict antibody responses. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14330-14335.	3.3	101

#	Article	IF	Citations
145	The history of MF59^{Â®}adjuvant: a phoenix that arose from the ashes. Expert Review of Vaccines, 2013, 12, 13-30.	2.0	254
146	Protective Efficacy Induced by Recombinant Clostridium difficile Toxin Fragments. Infection and Immunity, 2013, 81, 2851-2860.	1.0	38
147	Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19077-19082.	3.3	52
148	Perspectives on vaccine development for the elderly. Current Opinion in Immunology, 2013, 25, 529-534.	2.4	12
149	Introduction. Seminars in Immunology, 2013, 25, 87-88.	2.7	1
150	Immunisation against meningococcus B. Lancet, The, 2013, 382, 935-936.	6.3	1
151	Reverse vaccinology in the 21st century: improvements over the original design. Annals of the New York Academy of Sciences, 2013, 1285, 115-132.	1.8	77
152	Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infectious Diseases, The, 2013, 13, 416-425.	4.6	261
153	Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics. Science Translational Medicine, 2013, 5, 185ra68.	5.8	164
154	AflunovÂ®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opinion on Biological Therapy, 2013, 13, 121-135.	1.4	12
155	Conservation of Meningococcal Antigens in the Genus Neisseria. MBio, 2013, 4, e00163-13.	1.8	50
156	Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3304-3309.	3.3	125
157	The Gracefully Aging Immune System. Science Translational Medicine, 2013, 5, 185ps8.	5.8	124
158	Preventing Newborn Infection with Maternal Immunization. Science Translational Medicine, 2013, 5, 195ps11.	5.8	9
159	Optimized fluorescent labeling to identify memory B cells specific for Neisseria meningitidis serogroup B vaccine antigens ex vivo. Immunity, Inflammation and Disease, 2013, 1, 3-13.	1.3	5
160	The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 21095-21100.	3.3	125
161	Rapidly produced SAM^{Â®} vaccine against H7N9 influenza is immunogenic in mice. Emerging Microbes and Infections, 2013, 2, 1-7.	3.0	189
162	Vaccines, Reverse Vaccinology, and Bacterial Pathogenesis. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a012476-a012476.	2.9	119

#	Article	IF	Citations
163	Helicobacter pylori CagA: From Pathogenic Mechanisms to Its Use as an Anti-Cancer Vaccine. Frontiers in Immunology, 2013, 4, 328.	2.2	62
164	An Analysis of the Sequence Variability of Meningococcal fHbp, NadA and NHBA over a 50-Year Period in the Netherlands. PLoS ONE, 2013, 8, e65043.	1.1	47
165	Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines. Vaccine Journal, 2012, 19, 1609-1617.	3.2	59
166	RrgB321, a Fusion Protein of the Three Variants of the Pneumococcal Pilus Backbone RrgB, Is ProtectiveIn Vivoand Elicits Opsonic Antibodies. Infection and Immunity, 2012, 80, 451-460.	1.0	39
167	Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5229-5234.	3.3	111
168	Lack of Interference with Immunogenicity of a Chimeric Alphavirus Replicon Particle-Based Influenza Vaccine by Preexisting Antivector Immunity. Vaccine Journal, 2012, 19, 991-998.	3.2	18
169	ADITEC: Joining Forces for Next-Generation Vaccines. Science Translational Medicine, 2012, 4, 128cm4.	5.8	21
170	Toward a Meningitis-Free World. Science Translational Medicine, 2012, 4, 123ps5.	5.8	22
171	Human papillomavirus E2 protein: a potential key regulator of viral cell pathogenesis. Pathogens and Global Health, 2012, 106, 141-141.	1.0	0
172	Structural vaccinology starts to deliver. Nature Reviews Microbiology, 2012, 10, 807-813.	13.6	116
173	Vaccines and antibiotic resistance. Current Opinion in Microbiology, 2012, 15, 596-602.	2.3	90
174	The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens. Vaccine, 2012, 30, B87-B97.	1.7	309
175	Nonviral delivery of self-amplifying RNA vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14604-14609.	3.3	498
176	Improving influenza vaccines. Expert Review of Vaccines, 2012, 11, 871-872.	2.0	6
177	Recombinant bacterial vaccines. Current Opinion in Immunology, 2012, 24, 337-342.	2.4	25
178	Development of an Influenza virus Protein Array Using Sortagging Technology. Bioconjugate Chemistry, 2012, 23, 1119-1126.	1.8	19
179	The Factor H Binding Protein of Neisseria meningitidis Interacts with Xenosiderophores in Vitro. Biochemistry, 2012, 51, 9384-9393.	1.2	17
180	Influenza: Options to Improve Pandemic Preparation. Science, 2012, 336, 1531-1533.	6.0	71

#	Article	IF	Citations
181	Novel meningococcal 4<scp>CM</scp>enB vaccine antigens â€“ prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae. Apmis, 2012, 120, 750-760.	0.9	31
182	Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)-mediated adhesion and invasion. Cellular Microbiology, 2012, 14, 368-385.	1.1	28
183	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. PLoS ONE, 2012, 7, e48781.	1.1	56
184	Designing the Next Generation of Vaccines for Global Public Health. OMICS A Journal of Integrative Biology, 2011, 15, 545-566.	1.0	63
185	MF59 adjuvant: the best insurance against influenza strain diversity. Expert Review of Vaccines, 2011, 10, 447-462.	2.0	128
186	The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opinion on Drug Discovery, 2011, 6, 1045-1066.	2.5	167
187	Systems Vaccinomics: The Road Ahead for Vaccinology. OMICS A Journal of Integrative Biology, 2011, 15, 529-531.	1.0	37
188	Vi-CRM197 as a new conjugate vaccine against Salmonella Typhi. Vaccine, 2011, 29, 712-720.	1.7	80
189	Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine, 2011, 29, 1072-1081.	1.7	47
190	Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine, 2011, 29, 4739-4744.	1.7	98
191	Vaccine discovery and translation of new vaccine technology. Lancet, The, 2011, 378, 360-368.	6.3	89
192	Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children. Pediatric Infectious Disease Journal, 2011, 30, 1081-1085.	1.1	277
193	Influenza vaccine immunology. Immunological Reviews, 2011, 239, 167-177.	2.8	146
194	Vaccines for the twenty-first century society. Nature Reviews Immunology, 2011, 11, 865-872.	10.6	328
195	A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature, 2011, 473, 463-469.	13.7	236
196	Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: Use as a conjugation protein in vaccines and other potential clinical applications. Biologicals, 2011, 39, 195-204.	0.5	104
197	Escherichia coliHeat-Labile Enterotoxin Promotes Protective Th17 Responses against Infection by Driving Innate IL-1 and IL-23 Production. Journal of Immunology, 2011, 186, 5896-5906.	0.4	94
198	A novel epigenetic regulator associated with the hypervirulent Neisseria meningitidis clonal complex 41/44. FASEB Journal, 2011, 25, 3622-3633.	0.2	39

#	Article	IF	Citations
199	Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity. Science Translational Medicine, 2011, 3, 91ra62.	5.8	135
200	Efficacy of Vaccination with Different Combinations of MF59-Adjuvanted and Nonadjuvanted Seasonal and Pandemic Influenza Vaccines against Pandemic H1N1 (2009) Influenza Virus Infection in Ferrets. Journal of Virology, 2011, 85, 2851-2858.	1.5	46
201	MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines. Science Translational Medicine, 2011, 3, 85ra48.	5.8	304
202	Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. Journal of Molecular Cell Biology, 2011, 3, 144-146.	1.5	4
203	Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4494-4499.	3.3	198
204	Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9238-9243.	3.3	205
205	Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11169-11174.	3.3	149
206	Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9619-9624.	3.3	233
207	A sweet T cell response. Nature Medicine, 2011, 17, 1551-1552.	15.2	32
208	Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 10278-10283.	3.3	132
209	Transcriptome Analysis of Neisseria meningitidis in Human Whole Blood and Mutagenesis Studies Identify Virulence Factors Involved in Blood Survival. PLoS Pathogens, 2011, 7, e1002027.	2.1	129
210	Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies. Infection and Immunity, 2011, 79, 970-981.	1.0	64
211	Towards a vaccine against Escherichia coli-associated urinary tract infections. Future Microbiology, 2010, 5, 351-354.	1.0	5
212	GITR contributes to the systemic adjuvanticity of the Escherichia coli heatâ€labile enterotoxin. European Journal of Immunology, 2010, 40, 754-763.	1.6	3
213	New adjuvants for human vaccines. Current Opinion in Immunology, 2010, 22, 411-416.	2.4	352
214	Reverse Vaccinology: Developing Vaccines in the Era of Genomics. Immunity, 2010, 33, 530-541.	6.6	422
215	Jeanâ€Marc Reyrat (29/04/1967â€“28/10/2009). Molecular Microbiology, 2010, 75, 1059-1060.	1.2	0
216	Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nature Reviews Microbiology, 2010, 8, 393-399.	13.6	110

#	Article	IF	Citations
217	Supramolecular Organization of the Repetitive Backbone Unit of the Streptococcus pneumoniae Pilus. PLoS ONE, 2010, 5, e10919.	1.1	52
218	A Crisis of Public Confidence in Vaccines. Science Translational Medicine, 2010, 2, 61mr1.	5.8	131
219	Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus. Science Translational Medicine, 2010, 2, 15ra5.	5.8	242
220	Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3770-3775.	3.3	184
221	H1N1: Can a Pandemic Cycle Be Broken?. Science Translational Medicine, 2010, 2, 24ps14.	5.8	6
222	Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9072-9077.	3.3	222
223	Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19490-19495.	3.3	267
224	Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine, 2010, 28, 2416-2427.	1.7	33
225	Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine, 2010, 28, 5023-5030.	1.7	79
226	Evaluation of a Group A Streptococcus synthetic oligosaccharide as vaccine candidate. Vaccine, 2010, 29, 104-114.	1.7	74
227	Building an insurance against modern pandemics. Current Opinion in Investigational Drugs, 2010, 11, 126-30.	2.3	1
228	Identification of an Iron-Sulfur Cluster That Modulates the Enzymatic Activity in NarE, a Neisseria meningitidis ADP-ribosyltransferase. Journal of Biological Chemistry, 2009, 284, 33040-33047.	1.6	10
229	Investigation on the Effect of Immune Selection on Resistance to Bactericidal Antibodies to Group B Meningococci In Vitro. Vaccine Journal, 2009, 16, 1693-1695.	3.2	4
230	Rethinking Influenza. Science, 2009, 326, 50-50.	6.0	17
231	Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37. Infection and Immunity, 2009, 77, 292-299.	1.0	99
232	SR-A, MARCO and TLRs Differentially Recognise Selected Surface Proteins from Neisseria meningitidis: an Example of Fine Specificity in Microbial Ligand Recognition by Innate Immune Receptors. Journal of Innate Immunity, 2009, 1, 153-163.	1.8	38
233	The Key Role of Genomics in Modern Vaccine and Drug Design for Emerging Infectious Diseases. PLoS Genetics, 2009, 5, e1000612.	1.5	184
234	Seasonal Influenza Vaccine Provides Priming for A/H1N1 Immunization. Science Translational Medicine, 2009, 1, 12re1.	5.8	45

#	Article	IF	Citations
235	Solution Structure of the Factor H-binding Protein, a Survival Factor and Protective Antigen of Neisseria meningitidis. Journal of Biological Chemistry, 2009, 284, 9022-9026.	1.6	55
236	Sortase A Confers Protection against Streptococcus pneumoniae in Mice. Infection and Immunity, 2009, 77, 2957-2961.	1.0	24
237	Genetically Detoxified Pertussis Toxin Induces Th1/Th17 Immune Response through MAPKs and IL-10-Dependent Mechanisms. Journal of Immunology, 2009, 183, 1892-1899.	0.4	55
238	Adjuvanted H5N1 vaccine induces early CD4⁺T cell response that predicts long-term persistence of protective antibody levels. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3877-3882.	3.3	242
239	The use of genomics in microbial vaccine development. Drug Discovery Today, 2009, 14, 252-260.	3.2	131
240	Involvement of the intrinsic and extrinsic cellâ€death pathways in the induction of apoptosis of mature lymphocytes by the Escherichia coli heatâ€labile enterotoxin. European Journal of Immunology, 2009, 39, 439-446.	1.6	12
241	Generating memory with vaccination. European Journal of Immunology, 2009, 39, 2100-2105.	1.6	52
242	Molecular architecture of Streptococcus pneumoniae TIGR4 pili. EMBO Journal, 2009, 28, 3921-3930.	3.5	95
243	HadA is an atypical new multifunctional trimeric coiled-coil adhesin ofHaemophilus influenzaebiogroupaegyptius, which promotes entry into host cells. Cellular Microbiology, 2009, 11, 1044-1063.	1.1	35
244	Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine, 2009, 27, 1579-1584.	1.7	47
245	Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine, 2009, 27, 2794-2803.	1.7	111
246	Epitope Mapping of a Bactericidal Monoclonal Antibody against the Factor H Binding Protein of Neisseria meningitidis. Journal of Molecular Biology, 2009, 386, 97-108.	2.0	44
247	Vaccinology in the genome era. Journal of Clinical Investigation, 2009, 119, 2515-2525.	3.9	132
248	Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin. PLoS ONE, 2009, 4, e6999.	1.1	260
249	Development of vaccinesagainst Helicobacter pylori. Expert Review of Vaccines, 2009, 8, 1037-1049.	2.0	81
250	Alum adjuvanticity: Unraveling a century old mystery. European Journal of Immunology, 2008, 38, 2068-2071.	1.6	204
251	Toll-free immunity?. Nature Medicine, 2008, 14, 1318-1319.	15.2	6
252	Microbiology in the post-genomic era. Nature Reviews Microbiology, 2008, 6, 419-430.	13.6	324

#	Article	IF	Citations
253	Co-Stimulation of T cells via CD28 inhibits human IgE production; reversal by Pertussis toxin. Clinical and Experimental Immunology, 2008, 99, 473-478.	1.1	14
254	Structure-based antigen design: a strategy for next generation vaccines. Trends in Biotechnology, 2008, 26, 659-667.	4.9	143
255	A Second Pilus Type in Streptococcus pneumoniae Is Prevalent in Emerging Serotypes and Mediates Adhesion to Host Cells. Journal of Bacteriology, 2008, 190, 5480-5492.	1.0	159
256	Vaccine adjuvants: The dream becomes real. Hum Vaccin, 2008, 4, 347-349.	2.4	63
257	Pneumococcal Pili Are Composed of Protofilaments Exposing Adhesive Clusters of Rrg A. PLoS Pathogens, 2008, 4, e1000026.	2.1	114
258	Transcutaneous Immunization with Cross-Reacting Material CRM ₁₉₇ of Diphtheria Toxin Boosts Functional Antibody Levels in Mice Primed Parenterally with Adsorbed Diphtheria Toxoid Vaccine. Infection and Immunity, 2008, 76, 1766-1773.	1.0	18
259	Genomeâ€based vaccine development: A short cut for the future. Hum Vaccin, 2008, 4, 184-188.	2.4	36
260	Molecular and cellular signatures of human vaccine adjuvants. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10501-10506.	3.3	423
261	Pilus Operon Evolution in Streptococcus pneumoniae Is Driven by Positive Selection and Recombination. PLoS ONE, 2008, 3, e3660.	1.1	21
262	Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5115-5120.	3.3	521
263	Clonal success of piliated penicillin nonsusceptible pneumococci. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12907-12912.	3.3	91
264	The Acquired Immune Response to the Mucosal Adjuvant LTK63 Imprints the Mouse Lung with a Protective Signature. Journal of Immunology, 2007, 179, 5346-5357.	0.4	29
265	Invariant NKT cells sustain specific B cell responses and memory. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3984-3989.	3.3	213
266	Streptococcus pneumoniae Pilus Subunits Protect Mice against Lethal Challenge. Infection and Immunity, 2007, 75, 1059-1062.	1.0	127
267	Expression and selective upâ€regulation of toxinâ€related mono ADPâ€ribosyltransferases by pathogenâ€associated molecular patterns in alveolar epithelial cells. FEBS Letters, 2007, 581, 4199-4204.	1.3	12
268	Bridging the knowledge gaps in vaccine design. Nature Biotechnology, 2007, 25, 1361-1366.	9.4	168
269	Identification of a new OmpA-like protein in Neisseria gonorrhoeae involved in the binding to human epithelial cells and in vivo colonization. Molecular Microbiology, 2007, 64, 1391-1403.	1.2	40
270	RrgA is a pilusâ€associated adhesin in Streptococcus pneumoniae. Molecular Microbiology, 2007, 66, 329-340.	1.2	142

#	Article	IF	Citations
271	The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. Drug Discovery Today, 2007, 12, 429-439.	3.2	110
272	Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene. Vaccine Journal, 2006, 13, 1010-1013.	3.2	70
273	Mechanisms of pathogenesis and prevention of meningococcal disease. Drug Discovery Today Disease Mechanisms, 2006, 3, 273-279.	0.8	0
274	Meningococcal diseases: From genomes to vaccines. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 129-136.	0.5	1
275	Post-genomic vaccine development. FEBS Letters, 2006, 580, 2985-2992.	1.3	113
276	Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Current Opinion in Microbiology, 2006, 9, 532-536.	2.3	76
277	Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine, 2006, 24, 2161-2168.	1.7	49
278	Neisseria meningitidis group B correlates of protection and assay standardizationâ€"International Meeting Report Emory University, Atlanta, Georgia, United States, 16â€"17 March 2005. Vaccine, 2006, 24, 5093-5107.	1.7	168
279	Neisseria meningitidis NhhA is a multifunctional trimeric autotransporter adhesin. Molecular Microbiology, 2006, 61, 631-644.	1.2	82
280	Oral Spray Immunization May Be an Alternative to Intranasal Vaccine Delivery to Induce Systemic Antibodies but not Nasal Mucosal or Cellular Immunity. Scandinavian Journal of Immunology, 2006, 63, 223-231.	1.3	33
281	Vaccine manufacturing: challenges and solutions. Nature Biotechnology, 2006, 24, 1377-1383.	9.4	288
282	Pili in Gram-positive pathogens. Nature Reviews Microbiology, 2006, 4, 509-519.	13.6	388
283	Group B Streptococcus: global incidence and vaccine development. Nature Reviews Microbiology, 2006, 4, 932-942.	13.6	272
284	Novel approaches to pediatric vaccine deliveryâ˜†. Advanced Drug Delivery Reviews, 2006, 58, 29-51.	6.6	34
285	Solution Structure of the Immunodominant Domain of Protective Antigen GNA1870 of Neisseria meningitidis. Journal of Biological Chemistry, 2006, 281, 7220-7227.	1.6	37
286	A universal vaccine for serogroup B meningococcus. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10834-10839.	3.3	657
287	In Vivo Dissection of the Helicobacter pylori Fur Regulatory Circuit by Genome-Wide Location Analysis. Journal of Bacteriology, 2006, 188, 4654-4662.	1.0	86
288	Effect of Neisseria meningitidis Fur Mutations on Global Control of Gene Transcription. Journal of Bacteriology, 2006, 188, 2483-2492.	1.0	56

#	Article	IF	Citations
289	A pneumococcal pilus influences virulence and host inflammatory responses. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2857-2862.	3.3	395
290	Mucosal Administration of Ag85B-ESAT-6 Protects against Infection withMycobacterium tuberculosisand Boosts Prior Bacillus Calmette-Guèrin Immunity. Journal of Immunology, 2006, 177, 6353-6360.	0.4	168
291	Identification of Neisseria meningitidis Nonlipopolysaccharide Ligands for Class A Macrophage Scavenger Receptor by Using a Novel Assay. Infection and Immunity, 2006, 74, 5191-5199.	1.0	53
292	Group BStreptococcusCrosses Human Epithelial Cells by a Paracellular Route. Journal of Infectious Diseases, 2006, 193, 241-250.	1.9	56
293	Wild-type wine Saccharomyces cerevisiae as a tool to evaluate the effects on eukaryotic life of locally used herbicides. International Journal of Ecodynamics, 2006, 1, 266-283.	0.4	3
294	Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. Microbes and Infection, 2005, 7, 1386-1391.	1.0	16
295	The response of primary articular chondrocytes to micrometric surface topography and sulphated hyaluronic acid-based matrices. Cell Biology International, 2005, 29, 605-615.	1.4	32
296	Vaccinology at the beginning of the 21st century. Current Opinion in Immunology, 2005, 17, 411-418.	2.4	82
297	Ng-MIP, a surface-exposed lipoprotein ofNeisseria gonorrhoeae, has a peptidyl-prolylcis/transisomerase (PPIase) activity and is involved in persistence in macrophages. Molecular Microbiology, 2005, 58, 669-681.	1.2	107
298	Cell entry machines: a common theme in nature?. Nature Reviews Microbiology, 2005, 3, 349-358.	13.6	30
299	The impact of genomics on vaccine design. Trends in Biotechnology, 2005, 23, 84-91.	4.9	83
300	The Escherichia coli heat-labile enterotoxin induces apoptosis of immature lymphocytesin vivo via a glucocorticoid-dependent pathway. European Journal of Immunology, 2005, 35, 3505-3515.	1.6	8
301	SARS Vaccine Protective in Mice. Emerging Infectious Diseases, 2005, 11, 1312-1314.	2.0	42
302	SARS: Understanding the Virus and Development of Rational Therapy. Current Molecular Medicine, 2005, 5, 677-697.	0.6	23
303	Genome Analysis Reveals Pili in Group B Streptococcus. Science, 2005, 309, 105-105.	6.0	278
304	In Vitro Analysis of Protein-Operator Interactions of the NikR and Fur Metal-Responsive Regulators of Coregulated Genes in Helicobacter pylori. Journal of Bacteriology, 2005, 187, 7703-7715.	1.0	89
305	CrgA Is an Inducible LysR-Type Regulator of Neisseria meningitidis , Acting both as a Repressor and as an Activator of Gene Transcription. Journal of Bacteriology, 2005, 187, 3421-3430.	1.0	58
306	Modulation of the Immune Response to the Severe Acute Respiratory Syndrome Spike Glycoprotein by Gene-Based and Inactivated Virus Immunization. Journal of Virology, 2005, 79, 13915-13923.	1.5	39

#	Article	IF	Citations
307	Combined Conjugate Vaccines: Enhanced Immunogenicity with the N19 Polyepitope as a Carrier Protein. Infection and Immunity, 2005, 73, 5835-5841.	1.0	32
308	A novel glyco-conjugate vaccine against fungal pathogens. Journal of Experimental Medicine, 2005, 202, 597-606.	4.2	409
309	Induction of Protective Serum Meningococcal Bactericidal and Diphtheria-Neutralizing Antibodies and Mucosal Immunoglobulin A in Volunteers by Nasal Insufflations of the Neisseria meningitidis Serogroup C Polysaccharide-CRM197 Conjugate Vaccine Mixed with Chitosan. Infection and Immunity, 2005, 73, 8256-8265.	1.0	60
310	The Region Comprising Amino Acids 100 to 255 of Neisseria meningitidis Lipoprotein GNA 1870 Elicits Bactericidal Antibodies. Infection and Immunity, 2005, 73, 1151-1160.	1.0	88
311	A Non-Living Nasal Influenza Vaccine Can Induce Major Humoral and Cellular Immune Responses in Humans without the Need for Adjuvants. Hum Vaccin, 2005, 1, 85-90.	2.4	22
312	Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: Implications for the microbial "pan-genome". Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13950-13955.	3.3	2,161
313	Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen. Science, 2005, 309, 148-150.	6.0	497
314	The Diphtheria and Pertussis Components of Diphtheriaâ€Tetanus Toxoidsâ€“Pertussis Vaccine Should Be Genetically Inactivated Mutant Toxins. Journal of Infectious Diseases, 2005, 191, 81-88.	1.9	34
315	The microbial pan-genome. Current Opinion in Genetics and Development, 2005, 15, 589-594.	1.5	1,151
316	Reverse Vaccinology and Vaccines for Serogroup B Neisseria meningitidis. , 2005, 568, 217-223.		41
317	Application of Microbial Genomic Science to Advanced Therapeutics. Annual Review of Medicine, 2005, 56, 459-474.	5.0	39
318	Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. Journal of Drug Targeting, 2005, 13, 489-498.	2.1	46
319	NadA Diversity and Carriage in Neisseria meningitidis. Infection and Immunity, 2004, 72, 4217-4223.	1.0	127
320	Modulation of Immune Response to Group C Meningococcal Conjugate Vaccine Given Intranasally to Mice Together with the LTK63 Mucosal Adjuvant and the Trimethyl Chitosan Delivery System. Journal of Infectious Diseases, 2004, 189, 828-832.	1.9	49
321	Therapeutic Vaccination against Helicobacter pylori in the Beagle Dog Experimental Model: Safety, Immunogenicity, and Efficacy. Infection and Immunity, 2004, 72, 3252-3259.	1.0	81
322	Successful Induction of Protective Antibody Responses againstHaemophilus influenzaeType b and Diphtheria after Transcutaneous Immunization with the Glycoconjugate Polyribosyl Ribitol Phosphateâ€“Crossâ€Reacting Material197Vaccine. Journal of Infectious Diseases, 2004, 190, 1177-1182.	1.9	24
323	Effect of heparin binding on Helicobacter pylori resistance to serum. Journal of Medical Microbiology, 2004, 53, 9-12.	0.7	13
324	Mucosal Vaccination against Serogroup B Meningococci: Induction of Bactericidal Antibodies and Cellular Immunity following Intranasal Immunization with NadA of Neisseria meningitidis and Mutants of Escherichia coli Heat-Labile Enterotoxin. Infection and Immunity, 2004, 72, 4052-4060.	1.0	59

#	Article	IF	Citations
325	Dual Control of Helicobacter pylori Heat Shock Gene Transcription by HspR and HrcA. Journal of Bacteriology, 2004, 186, 2956-2965.	1.0	34
326	Putative Vaccine Antigens fromNeisseria meningitidisRecognized by Serum Antibodies of Young Children Convalescing after Meningococcal Disease. Journal of Infectious Diseases, 2004, 190, 1488-1497.	1.9	72
327	Synthesis and Characterization of a Native, Oligomeric Form of Recombinant Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein. Journal of Virology, 2004, 78, 10328-10335.	1.5	117
328	GNA33 of Neisseria meningitidis Is a Lipoprotein Required for Cell Separation, Membrane Architecture, and Virulence. Infection and Immunity, 2004, 72, 1914-1919.	1.0	51
329	Innate Imprinting by the Modified Heat-Labile Toxin of Escherichia coli (LTK63) Provides Generic Protection against Lung Infectious Disease. Journal of Immunology, 2004, 173, 7435-7443.	0.4	62
330	Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Molecular Microbiology, 2004, 55, 687-698.	1.2	206
331	Inside sensors detecting outside pathogens. Nature Immunology, 2004, 5, 1099-1100.	7.0	12
332	An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nature Medicine, 2004, 10, 871-875.	15.2	679
333	From Pasteur to genomics: progress and challenges in infectious diseases. Nature Medicine, 2004, 10, 1177-1185.	15.2	98
334	Fur functions as an activator and as a repressor of putative virulence genes in Neisseria meningitidis. Molecular Microbiology, 2004, 52, 1081-1090.	1.2	168
335	The safety of vaccines. Drug Discovery Today, 2004, 9, 846-854.	3.2	36
336	Helicobacter pylori Infection Negatively Influences Pregnancy Outcome in a Mouse Model. Helicobacter, 2004, 9, 152-157.	1.6	22
337	Novel Approaches to Vaccine Delivery. Pharmaceutical Research, 2004, 21, 1519-1530.	1.7	119
338	N19 Polyepitope as a Carrier for Enhanced Immunogenicity and Protective Efficacy of Meningococcal Conjugate Vaccines. Infection and Immunity, 2004, 72, 4884-4887.	1.0	27
339	Long-term solutions for the problem of vaccine shortages. Expert Opinion on Biological Therapy, 2004, 4, 989-992.	1.4	4
340	Genome-derived vaccines. Expert Review of Vaccines, 2004, 3, 59-76.	2.0	74
341	Models for bacterial infectious diseases: Helicobacter pylori. Drug Discovery Today: Disease Models, 2004, 1, 95-100.	1.2	1
342	Safety and immunogenicity in animals of subunit influenza vaccine given intranasally with mutants of Escherichia coli heat-labile enterotoxin (LT). International Congress Series, 2004, 1263, 640-643.	0.2	0

#	Article	IF	Citations
343	In silico identification of novel bacterial ADP-ribosyltransferases. International Journal of Medical Microbiology, 2004, 293, 471-478.	1.5	26
344	The multiple cellular activities of the VacA cytotoxin of Helicobacter pylori. International Journal of Medical Microbiology, 2004, 293, 589-597.	1.5	31
345	Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens. Journal of Biotechnology, 2004, 113, 15-32.	1.9	49
346	The genome revolution in vaccine research. Current Issues in Molecular Biology, 2004, 6, 17-27.	1.0	45
347	Reverse vaccinology. Drug Discovery Today, 2003, 8, 459-464.	3.2	117
348	The neutrophil-activating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophils. European Journal of Immunology, 2003, 33, 840-849.	1.6	48
349	Phase I Safety and Immunogenicity of A Three-Component H. Pylori Vaccine. Clinical Pharmacology and Therapeutics, 2003, 73, P34-P34.	2.3	2
350	The quest for a vaccine against Helicobacter pylori: how to move from mouse to man?. Microbes and Infection, 2003, 5, 749-756.	1.0	51
351	An anti-repression Fur operator upstream of the promoter is required for iron-mediated transcriptional autoregulation in Helicobacter pylori. Molecular Microbiology, 2003, 50, 1329-1338.	1.2	38
352	NarE: a novel ADPâ€ribosyltransferase from Neisseria meningitidis. Molecular Microbiology, 2003, 50, 1055-1067.	1.2	45
353	Neisseria meningitidis App, a new adhesin with autocatalytic serine protease activity. Molecular Microbiology, 2003, 48, 323-334.	1.2	94
354	SARS â€" beginning to understand a new virus. Nature Reviews Microbiology, 2003, 1, 209-218.	13.6	469
355	Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Review of Vaccines, 2003, 2, 285-293.	2.0	103
356	The real cost of an affordable vaccine for meningococcus A. Lancet, The, 2003, 362, 250-251.	6.3	4
357	Two years into reverse vaccinology. Vaccine, 2003, 21, 605-610.	1.7	109
358	vir90, a virulence-activated gene coding for a Bordetella pertussis iron-regulated outer membrane protein. Research in Microbiology, 2003, 154, 443-450.	1.0	13
359	Reverse Vaccinology and Genomics. Science, 2003, 302, 602-602.	6.0	83
360	Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin A. Infection and Immunity, 2003, 71, 726-732.	1.0	110

#	Article	IF	Citations
361	Antibody to Genomeâ€Derived Neisserial Antigen 2132, aNeisseria meningitidisCandidate Vaccine, Confers Protection against Bacteremia in the Absence of Complementâ€Mediated Bactericidal Activity. Journal of Infectious Diseases, 2003, 188, 1730-1740.	1.9	129
362	Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870. Journal of Experimental Medicine, 2003, 197, 789-799.	4.2	388
363	The Iron-Responsive Regulator Fur Is Transcriptionally Autoregulated and Not Essential in Neisseria meningitidis. Journal of Bacteriology, 2003, 185, 6032-6041.	1.0	41
364	Transcutaneous Immunization with Tetanus Toxoid and Mutants ofEscherichia coliHeatâ€Labile Enterotoxin as Adjuvants Elicits Strong Protective Antibody Responses. Journal of Infectious Diseases, 2003, 188, 753-758.	1.9	54
365	Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9542-9547.	3.3	191
366	Phylogeny of the SARS Coronavirus. Science, 2003, 302, 1504b-1505.	6.0	79
367	Helicobacter pylori. Journal of Experimental Medicine, 2003, 197, 807-811.	4.2	14
368	Growth Phase-Dependent Regulation of Target Gene Promoters for Binding of the Essential Orphan Response Regulator HP1043 of Helicobacter pylori. Journal of Bacteriology, 2002, 184, 4800-4810.	1.0	56
369	NadA, a Novel Vaccine Candidate of Neisseria meningitidis. Journal of Experimental Medicine, 2002, 195, 1445-1454.	4.2	337
370	The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enhances the Ability of Peptide Antigens To Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin. Infection and Immunity, 2002, 70, 3012-3019.	1.0	34
371	Bacterial pathogen genomics and vaccines. British Medical Bulletin, 2002, 62, 45-58.	2.7	21
372	Characterization of the HspR-Mediated Stress Response in Helicobacter pylori. Journal of Bacteriology, 2002, 184, 2925-2930.	1.0	27
373	Characterization and Immunogenicity of the CagF Protein of the cag Pathogenicity Island of Helicobacter pylori. Infection and Immunity, 2002, 70, 6468-6470.	1.0	11
374	Helicobacter pylori Interactions with Host Serum and Extracellular Matrix Proteins: Potential Role in the Infectious Process. Microbiology and Molecular Biology Reviews, 2002, 66, 617-629.	2.9	55
375	Enhancement of Protective Efficacy following Intranasal Immunization with Vaccine Plus a Nontoxic LTK63 Mutant Delivered with Nanoparticles. Infection and Immunity, 2002, 70, 4785-4790.	1.0	57
376	Reverse vaccinology: a genome-based approach for vaccine development. Expert Opinion on Biological Therapy, 2002, 2, 895-905.	1.4	57
377	Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12391-12396.	3.3	447
378	MEDICINE: The Intangible Value of Vaccination. Science, 2002, 297, 937-939.	6.0	151

#	Article	IF	Citations
379	New strategies for the prevention and treatment of Helicobacter pylori infection. Expert Opinion on Investigational Drugs, 2002, 11, 1127-1138.	1.9	12
380	Structure of the Neutrophil-activating Protein from Helicobacter pylori. Journal of Molecular Biology, 2002, 323, 125-130.	2.0	133
381	Problems in identifying microbial-derived neutrophil activators, focusing on Helicobacter pylori. Trends in Microbiology, 2002, 10, 14.	3.5	0
382	In vitro selection of high affinity HspR-binding sites within the genome of Helicobacter pylori. Gene, 2002, 283, 63-69.	1.0	15
383	Antibody-dependent macrophage-mediated activity against Helicobacter pylori in the absence of complement. European Journal of Immunology, 2002, 32, 2721-2725.	1.6	8
384	The Fur repressor controls transcription of iron-activated and -repressed genes in Helicobacter pylori. Molecular Microbiology, 2002, 42, 1297-1309.	1.2	167
385	c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Molecular Microbiology, 2002, 43, 971-980.	1.2	393
386	Autoregulation of Helicobacter pylori Fur revealed by functional analysis of the iron-binding site. Molecular Microbiology, 2002, 46, 1107-1122.	1.2	68
387	GNA33 fromNeisseria meningitidisserogroup B encodes a membrane-bound lytic transglycosylase (MltA). FEBS Journal, 2002, 269, 3722-3731.	0.2	37
388	Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nature Biotechnology, 2002, 20, 914-921.	9.4	205
389	Evolution of functional polymorphism in the gene coding for theHelicobacter pyloricytotoxin. FEMS Microbiology Letters, 2002, 206, 253-258.	0.7	18
390	The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells. European Journal of Immunology, 2002, 32, 671.	1.6	76
391	Reverse vaccinology, a genome-based approach to vaccine development. Vaccine, 2001, 19, 2688-2691.	1.7	381
392	Hostâ€“microbe interactions: bacteria. Current Opinion in Microbiology, 2001, 4, 13-15.	2.3	3
393	Problems in assaying neutrophil activators. Trends in Microbiology, 2001, 9, 314-315.	3.5	1
394	An abundance of bacterial ADP-ribosyltransferases â€“ implications for the origin of exotoxins and their human homologues. Trends in Microbiology, 2001, 9, 308.	3.5	0
395	Vacuolation induced by VacA toxin ofHelicobacter pylorirequires the intracellular accumulation of membrane permeant bases, Clâ^'and water. FEBS Letters, 2001, 508, 479-483.	1.3	30
396	THEDESIGN OFVACCINESAGAINSTHELICOBACTER PYLORIANDTHEIRDEVELOPMENT. Annual Review of Immunology, 2001, 19, 523-563.	9.5	206

#	Article	IF	Citations
397	Allelic variation in the vacA gene of Helicobacter pylori isolated from Chinese patients. Chinese Journal of Digestive Diseases, 2001, 2, 17.	1.1	0
398	Rationally designed strings of promiscuous CD4+ T cell epitopes provide help toHaemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. European Journal of Immunology, 2001, 31, 3816-3824.	1.6	49
399	Neutrophil-activating protein (HP-NAP) versus ferritin (Pfr): comparison of synthesis in Helicobacter pylori. FEMS Microbiology Letters, 2001, 199, 143-149.	0.7	39
400	Living dangerously: how Helicobacter pylori survives in the human stomach. Nature Reviews Molecular Cell Biology, 2001, 2, 457-466.	16.1	447
401	The Binding Subunit of Pertussis Toxin Inhibits HIV Replication in Human Macrophages and Virus Expression in Chronically Infected Promonocytic U1 Cells. Journal of Immunology, 2001, 166, 1863-1870.	0.4	33
402	A Novel Mimetic Antigen Eliciting Protective Antibody toNeisseria meningitidis. Journal of Immunology, 2001, 167, 6487-6496.	0.4	51
403	Induction of Neutralizing Antibodies against Diphtheria Toxin by Priming with Recombinant Mycobacterium bovis BCG Expressing CRM197, a Mutant Diphtheria Toxin. Infection and Immunity, 2001, 69, 869-874.	1.0	37
404	Mu-Like Prophage in Serogroup B Neisseria meningitidis Coding for Surface-Exposed Antigens. Infection and Immunity, 2001, 69, 2580-2588.	1.0	47
405	Reversal of the CD4+/CD8+T-Cell Ratio in Lymph Node Cells upon In Vitro Mitogenic Stimulation by Highly Purified, Water-Soluble S3-S4 Dimer of Pertussis Toxin. Infection and Immunity, 2001, 69, 3073-3081.	1.0	17
406	Iron-Dependent Transcription of the frpB Gene of Helicobacter pylori Is Controlled by the Fur Repressor Protein. Journal of Bacteriology, 2001, 183, 4932-4937.	1.0	71
407	Characterization of the Antibody Response to Pneumococcal Glycoconjugates and the Effect of Heatâ€Labile Enterotoxin on IgG Subclasses after Intranasal Immunization. Journal of Infectious Diseases, 2001, 183, 1494-1500.	1.9	26
408	Intranasal Immunization with SAG1 and Nontoxic Mutant Heat-Labile Enterotoxins Protects Mice againstToxoplasma gondii. Infection and Immunity, 2001, 69, 1605-1612.	1.0	78
409	The Helicobacter pylori VacA toxin is a urea permease that promotes urea diffusion across epithelia. Journal of Clinical Investigation, 2001, 108, 929-937.	3.9	78
410	Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Molecular Microbiology, 2000, 37, 207-215.	1.2	231
411	Blocking bacterial enterotoxins. Nature Medicine, 2000, 6, 257-258.	15.2	4
412	The VacA toxin of Helicobacter pylori identifies a new intermediate filament-interacting protein. EMBO Journal, 2000, 19, 48-56.	3.5	56
413	Recombinant Mycobacterium bovis BCG Expressing Pertussis Toxin Subunit S1 Induces Protection against an Intracerebral Challenge with Live Bordetella pertussis in Mice. Infection and Immunity, 2000, 68, 4877-4883.	1.0	91
414	Cell Specificity of Helicobacter pylori Cytotoxin Is Determined by a Short Region in the Polymorphic Midregion. Infection and Immunity, 2000, 68, 3754-3757.	1.0	73

#	Article	IF	Citations
415	Modulation of Innate and Acquired Immune Responses byEscherichia coliHeat-Labile Toxin: Distinct Pro- and Anti-Inflammatory Effects of the Nontoxic AB Complex and the Enzyme Activity. Journal of Immunology, 2000, 165, 5750-5759.	0.4	101
416	Pushing the limits of cellular microbiology: Microarrays to study bacteria-host cell intimate contacts. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13467-13469.	3.3	52
417	The Neutrophil-Activating Protein (Hp-Nap) of Helicobacter pylori Is a Protective Antigen and a Major Virulence Factor. Journal of Experimental Medicine, 2000, 191, 1467-1476.	4.2	279
418	Immunohistochemical Study of Lymphocyte Populations Infiltrating the Gastric Mucosa of Beagle Dogs Experimentally Infected with Helicobacter pylori. Infection and Immunity, 2000, 68, 4769-4772.	1.0	28
419	Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1263-1268.	3.3	551
420	Tyrosine-Phosphorylated Bacterial Proteins. Journal of Experimental Medicine, 2000, 191, 587-592.	4.2	167
421	Reverse vaccinology. Current Opinion in Microbiology, 2000, 3, 445-450.	2.3	610
422	A structural overview of the Helicobacter cytotoxin. International Journal of Medical Microbiology, 2000, 290, 375-379.	1.5	13
423	LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. International Journal of Medical Microbiology, 2000, 290, 455-461.	1.5	21
424	Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58. Science, 2000, 287, 1809-1815.	6.0	1,083
425	Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing. Science, 2000, 287, 1816-1820.	6.0	1,258
426	Synthesis, chemical and rheological characterization of new hyaluronic acid-based hydrogels. Journal of Biomaterials Science, Polymer Edition, 2000, 11, 383-399.	1.9	56
427	Physicochemical characterisation of the pertussis vaccine. Developments in Biologicals, 2000, 103, 175-88.	0.4	0
428	Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides. Immunology Letters, 1999, 67, 209-216.	1.1	29
429	The Helicobacter pylori neutrophil-activating protein is an iron-binding protein with dodecameric structure. Molecular Microbiology, 1999, 34, 238-246.	1.2	159
430	Towards deciphering the Helicobacter pylori cytotoxin. Molecular Microbiology, 1999, 34, 197-204.	1.2	65
431	The Vaccine Containing Recombinant Pertussis Toxin Induces Early and Long-Lasting Protection. Biologicals, 1999, 27, 99-102.	0.5	16
432	Formation of anion-selective channels in the cell plasma membrane by the toxin VacA of Helicobacter pylori is required for its biological activity. EMBO Journal, 1999, 18, 5517-5527.	3.5	240

#	Article	IF	Citations
433	Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. Vaccine, 1999, 17, 1251-1263.	1.7	62
434	Inhibition of the vacuolating and anion channel activities of the VacA toxin ofHelicobacter pylori. FEBS Letters, 1999, 460, 221-225.	1.3	67
435	Helicobacter pylori Vacuolating Toxin Forms Anion-Selective Channels in Planar Lipid Bilayers: Possible Implications for the Mechanism of Cellular Vacuolation. Biophysical Journal, 1999, 76, 1401-1409.	0.2	145
436	3D imaging of the 58 kda cell binding subunit of the Helicobacter pylori cytotoxin. Journal of Molecular Biology, 1999, 290, 459-470.	2.0	77
437	Helicobacter pylori Virulence and Genetic Geography. Science, 1999, 284, 1328-1333.	6.0	998
438	Effects of Site-Directed Mutagenesis of Escherichia coli Heat-Labile Enterotoxin on ADP-Ribosyltransferase Activity and Interaction with ADP-Ribosylation Factors. Infection and Immunity, 1999, 67, 259-265.	1.0	19
439	Intranasal Immunization with Pneumococcal Polysaccharide Conjugate Vaccines with Nontoxic Mutants ofEscherichia coliHeat-Labile Enterotoxins as Adjuvants Protects Mice against Invasive Pneumococcal Infections. Infection and Immunity, 1999, 67, 5892-5897.	1.0	62
440	Mutants ofEscherichia coliHeat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells. Infection and Immunity, 1999, 67, 6270-6280.	1.0	88
441	A Conventional Beagle Dog Model for Acute and Chronic Infection withHelicobacter pylori. Infection and Immunity, 1999, 67, 3112-3120.	1.0	48
442	Genetically Detoxified Mutants of Heat-Labile Toxin from Escherichia coli Are Able To Act as Oral Adjuvants. Infection and Immunity, 1999, 67, 4400-4406.	1.0	70
443	MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. Journal of Immunology, 1999, 163, 6502-10.	0.4	75
444	Molecular approaches for safer and stronger vaccines. Swiss Medical Weekly, 1999, 129, 1744-8.	0.8	3
445	Characterisation of a monoclonal antibody and its use to purify the cytotoxin ofHelicobacter pylori. FEMS Microbiology Letters, 1998, 165, 79-84.	0.7	16
446	NMR studies on the structure/function correlations of T-cell-epitope analogs from pertussis toxin. FEBS Journal, 1998, 254, 313-317.	0.2	2
447	Sulphated hyaluronic acids: a chemical and biological characterisation. Polymer International, 1998, 46, 225-240.	1.6	33
448	Pathogenicity island mediatesHelicobacter pylori interaction with the host. Folia Microbiologica, 1998, 43, 275-278.	1.1	11
449	Action site and cellular effects of cytotoxin VacA produced byHelicobacter pylori. Folia Microbiologica, 1998, 43, 279-284.	1.1	14
450	Effects of the insertion of a nonapeptide from murine IL-1Î² on the immunogenicity of carrier proteins delivered by live attenuated Salmonella. Archives of Microbiology, 1998, 169, 113-119.	1.0	4

#	Article	IF	Citations
451	Functional analysis of theHelicobacter pyloriprincipal sigma subunit of RNA polymerase reveals that the spacer region is important for efficient transcription. Molecular Microbiology, 1998, 30, 121-134.	1.2	40
452	Helicobacter pylori: molecular evolution of a bacterial quasi-species. Current Opinion in Microbiology, 1998, 1, 96-102.	2.3	63
453	Molecular basis of vaccination. Molecular Aspects of Medicine, 1998, 19, 1-70.	2.7	17
454	TPA and butyrate increase cell sensitivity to the vacuolating toxin ofHelicobacter pylori. FEBS Letters, 1998, 436, 218-222.	1.3	12
455	The Acid Activation ofHelicobacter pyloriToxin VacA: Structural and Membrane Binding Studies. Biochemical and Biophysical Research Communications, 1998, 248, 334-340.	1.0	84
456	Cell vacuolization induced by Helicobacter pylori VacA toxin: cell line sensitivity and quantitative estimation. Toxicology Letters, 1998, 99, 109-115.	0.4	31
457	Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity. Journal of Experimental Medicine, 1998, 187, 1123-1132.	4.2	270
458	Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7- 1, B7-2 and CD28. International Immunology, 1998, 10, 651-662.	1.8	141
459	The m2 form of the Helicobacter pylori cytotoxin has cell type-specific vacuolating activity. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10212-10217.	3.3	184
460	Selective Inhibition of Ii-dependent Antigen Presentation by Helicobacter pylori Toxin VacA. Journal of Experimental Medicine, 1998, 187, 135-140.	4.2	270
461	7.6 Molecular Genetics of Bordetella Pertussis Virulence. Methods in Microbiology, 1998, 27, 395-406.	0.4	0
462	Levels of Expression and Immunogenicity of Attenuated Salmonella enterica Serovar Typhimurium Strains Expressing Escherichia coli Mutant Heat-Labile Enterotoxin. Infection and Immunity, 1998, 66, 224-231.	1.0	54
463	Identification of the Helicobacter pylori VacA Toxin Domain Active in the Cell Cytosol. Infection and Immunity, 1998, 66, 6014-6016.	1.0	102
464	Deletion of the Major Proteolytic Site of the Helicobacter pylori Cytotoxin Does Not Influence Toxin Activity but Favors Assembly of the Toxin into Hexameric Structures. Infection and Immunity, 1998, 66, 5547-5550.	1.0	23
465	A Recombinant Live Attenuated Strain of Vibrio cholerae Induces Immunity against Tetanus Toxin and Bordetella pertussis Tracheal Colonization Factor. Infection and Immunity, 1998, 66, 1648-1653.	1.0	28
466	Binding of the Helicobacter pylori Vacuolating Cytotoxin to Target Cells. Infection and Immunity, 1998, 66, 3981-3984.	1.0	59
467	Counterselectable Markers: Untapped Tools for Bacterial Genetics and Pathogenesis. Infection and Immunity, 1998, 66, 4011-4017.	1.0	234
468	Selective increase of the permeability of polarized epithelial cell monolayers by Helicobacter pylori vacuolating toxin.. Journal of Clinical Investigation, 1998, 102, 813-820.	3.9	221

#	Article	IF	Citations
469	Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization. Developments in Biological Standardization, 1998, 92, 123-6.	0.2	11
470	Effect of Helicobacter pylori Vacuolating Toxin on Maturation and Extracellular Release of Procathepsin D and on Epidermal Growth Factor Degradation. Journal of Biological Chemistry, 1997, 272, 25022-25028.	1.6	111
471	Vacuoles Induced by Helicobacter pylori Toxin Contain Both Late Endosomal and Lysosomal Markers. Journal of Biological Chemistry, 1997, 272, 25339-25344.	1.6	174
472	Identification and characterization of an operon of Helicobacter pylori that is involved in motility and stress adaptation. Journal of Bacteriology, 1997, 179, 4676-4683.	1.0	99
473	Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori?. Trends in Microbiology, 1997, 5, 205-208.	3.5	167
474	Meningococcal polysaccharide-protein conjugate vaccines. International Journal of Infectious Diseases, 1997, 1, 152-157.	1.5	16
475	Rational design of vaccines. Nature Medicine, 1997, 3, 374-376.	15.2	48
476	The small GTP binding protein rab7 is essential for cellular vacuolation induced by Helicobacter pylori cytotoxin. EMBO Journal, 1997, 16, 15-24.	3.5	203
477	Current Developments in New Vaccines for Adolescents. Biologicals, 1997, 25, 159-163.	0.5	1
478	Efficient production of heat-labile enterotoxin mutant proteins by overexpression of dsbA in a degP -deficient Escherichia coli strain. Archives of Microbiology, 1997, 167, 280-283.	1.0	33
479	Pertactin antigens extracted from Bordetella pertussis and Bordetella bronchiseptica differ in the isoelectric point. Archives of Microbiology, 1997, 168, 437-440.	1.0	0
480	Immunobiology of Helicobacter pylori infection. Current Opinion in Immunology, 1997, 9, 498-503.	2.4	79
481	A tRNA Arg 2 gene of Corynebacterium diphtheriae is the chromosomal integration site for toxinogenic bacteriophages. Molecular Microbiology, 1997, 25, 1179-1181.	1.2	24
482	Transcriptional analysis of the divergent cagAB genes encoded by the pathogenicity island of Helicobacter pylori. Molecular Microbiology, 1997, 26, 361-372.	1.2	56
483	Helicobacter pylori toxin VacA induces vacuole formation by acting in the cell cytosol. Molecular Microbiology, 1997, 26, 665-674.	1.2	128
484	Crystal structure of a nonâ€toxic mutant of heatâ€labile enterotoxin, which is a potent mucosal adjuvant. Protein Science, 1997, 6, 2650-2654.	3.1	22
485	Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infection and Immunity, 1997, 65, 331-334.	1.0	56
486	Detoxification of the Helicobacter pylori cytotoxin. Infection and Immunity, 1997, 65, 4615-4619.	1.0	26

#	Article	IF	Citations
487	Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infection and Immunity, 1997, 65, 4996-5002.	1.0	168
488	Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infection and Immunity, 1997, 65, 1045-1052.	1.0	40
489	Introduction of unmarked mutations in the Helicobacter pylori vacA gene with a sucrose sensitivity marker. Infection and Immunity, 1997, 65, 1949-1952.	1.0	102
490	Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infection and Immunity, 1997, 65, 2821-2828.	1.0	162
491	Evaluation of the recombinant 38-kilodalton antigen of Mycobacterium tuberculosis as a potential immunodiagnostic reagent. Journal of Clinical Microbiology, 1997, 35, 553-557.	1.8	80
492	Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease?. Developments in Biological Standardization, 1997, 89, 379-89.	0.2	11
493	Novel Molecular Biology Approaches to Acellular Vaccines. Biotechnology Annual Review, 1996, 2, 391-408.	2.1	7
494	Cellular Microbiology Emerging. Science, 1996, 271, 315-316.	6.0	169
495	DNA binding of the Bordetella pertussis H1 homolog alters in vitro DNA flexibility. Journal of Bacteriology, 1996, 178, 2982-2985.	1.0	7
496	cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 14648-14653.	3.3	1,801
497	The adjuvant effect of a nonâ€toxic mutant of heatâ€labile enterotoxin of Escherichia coli for the induction of measles virusâ€specific CTL responses after intranasal coâ€immunization with a synthetic peptide. Immunology, 1996, 89, 483-487.	2.0	74
498	Three conserved consensus sequences identify the NAD-binding site of ADP-ribosylating enzymes, expressed by eukaryotes, bacteria and T-even bacteriophages. Molecular Microbiology, 1996, 21, 667-674.	1.2	143
499	Differential binding of BvgA to two classes of virulence genes of Bordetella pertussis directs promoter selectivity by RNA polymerase. Molecular Microbiology, 1996, 21, 557-565.	1.2	53
500	The vacuolar ATPase proton pump is present on intracellular vacuoles induced by Helicobacter pylori. Journal of Medical Microbiology, 1996, 45, 84-89.	0.7	43
501	Detection of a Vacuolating Cytotoxin in Stools from Children with Diarrhea. Clinical Infectious Diseases, 1996, 23, 101-106.	2.9	15
502	Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin.. Journal of Cell Biology, 1996, 133, 801-807.	2.3	184
503	Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infection and Immunity, 1996, 64, 4172-4181.	1.0	65
504	Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin. Infection and Immunity, 1996, 64, 5434-5438.	1.0	37

#	Article	IF	Citations
505	Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infection and Immunity, 1996, 64, 974-979.	1.0	213
506	The pertussis toxin liberation genes of Bordetella pertussis are transcriptionally linked to the pertussis toxin operon. Infection and Immunity, 1996, 64, 1458-1460.	1.0	8
507	Acellular pertussis vaccines: a turning point in infant and adolescent vaccination. Infectious Agents and Disease, 1996, 5, 21-8.	1.2	11
508	The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization. Developments in Biological Standardization, 1996, 87, 125-34.	0.2	11
509	Genetic Detoxification of Bacterial Toxins: A New Approach to Vaccine Development. International Archives of Allergy and Immunology, 1995, 108, 327-333.	0.9	28
510	Improving membrane filtration processes. Trends in Biotechnology, 1995, 13, 129-131.	4.9	7
511	Lipid Interaction of the 37-kDa and 58-kDa Fragments of the Helicobacter Pylori Cytotoxin. FEBS Journal, 1995, 234, 947-952.	0.2	56
512	Both Immunization with Protein and Recombinant Vaccinia Virus Can Stimulate CTL Specific for the E7 Protein of Human Papilloma Virus 16 in H-2d Mice. Scandinavian Journal of Immunology, 1995, 42, 557-563.	1.3	39
513	Identification of errors among database sequence entries and comparison of correct amino acid sequences for the heat-labile enterotoxins of Escherichia coli and Vibrio cholerae. Molecular Microbiology, 1995, 15, 1165-1167.	1.2	39
514	A novel chromatin-forming histone H1 homologue is encoded by a dispensable and growth-regulated gene in Bordetella pertussis. Molecular Microbiology, 1995, 15, 871-881.	1.2	21
515	Low pH Activates the Vacuolating Toxin of Helicobacter pylori, Which Becomes Acid and Pepsin Resistant. Journal of Biological Chemistry, 1995, 270, 23937-23940.	1.6	197
516	Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 1644-1648.	3.3	298
517	Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science, 1995, 267, 1655-1658.	6.0	603
518	Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Journal of Pediatrics, 1995, 127, 238-243.	0.9	20
519	Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infection and Immunity, 1995, 63, 94-98.	1.0	547
520	Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infection and Immunity, 1995, 63, 4154-4160.	1.0	207
521	Helicobacter pylori cytotoxin: importance of native conformation for induction of neutralizing antibodies. Infection and Immunity, 1995, 63, 4476-4480.	1.0	96
522	Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies. Infection and Immunity, 1995, 63, 1102-1106.	1.0	90

#	Article	IF	Citations
523	A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infection and Immunity, 1995, 63, 2100-2108.	1.0	99
524	Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infection and Immunity, 1995, 63, 2356-2360.	1.0	81
525	IL-1 stimulates a diverging signaling pathway in EL4 6.1 thymoma cells. IL-2 release, but not IL-2 receptor expression, is sensitive to pertussis toxin. Journal of Immunology, 1995, 155, 181-9.	0.4	11
526	Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. Physiological Chemistry and Physics and Medical NMR, 1995, 27, 355-61.	0.2	8
527	A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit.. Journal of Experimental Medicine, 1994, 180, 2147-2153.	4.2	122
528	Development and Clinical Results with an Acellular Vaccine Containing Genetically Detoxified Pertussis Toxin. Biologicals, 1994, 22, 201.	0.5	0
529	Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: Potential new therapies and vaccines. Trends in Biotechnology, 1994, 12, 420-426.	4.9	82
530	Common features of the NAD-binding and catalytic site of ADP-ribosylating toxins. Molecular Microbiology, 1994, 14, 41-50.	1.2	118
531	Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Molecular Microbiology, 1994, 14, 51-60.	1.2	137
532	Mutations in the linker region of BvgS abolish response to environmental signals for the regulation of the virulence factors in Bordetella pertussis. Gene, 1994, 150, 123-127.	1.0	31
533	Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. Journal of Pediatrics, 1994, 124, 921-926.	0.9	38
534	Cellular vacuoles induced by Helicobacter pylori originate from late endosomal compartments.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9720-9724.	3.3	232
535	Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. Infection and Immunity, 1994, 62, 1830-1834.	1.0	61
536	Pertussis toxin activates platelets through an interaction with platelet glycoprotein Ib. Infection and Immunity, 1994, 62, 3108-3114.	1.0	28
537	Pertussis toxin interferes with superantigen-induced deletion of peripheral T cells without affecting T cell activation in vivo. Inhibition of deletion and associated programmed cell death depends on ADP-ribosyltransferase activity. Journal of Immunology, 1994, 152, 4291-9.	0.4	17
538	Development of the new acellular recombinant pertussis vaccine. Archives De L'Institut Pasteur De Tunis, 1994, 71, 557-63.	0.1	0
539	Environmental regulation of virulence factors inBordetellaspecies. BioEssays, 1993, 15, 99-104.	1.2	32
540	Bafilomycin A1 inhibits Helicobacter pylori-induced vacuolization of HeLa cells. Molecular Microbiology, 1993, 7, 323-327.	1.2	134

#	Article	IF	Citations
541	Pertussis toxin export requires accessory genes located downstream from the pertussis toxin operon. Molecular Microbiology, 1993, 8, 429-434.	1.2	108
542	The Hsp60 protein of Helicobacter pylori: structure and immune response in patients with gastroduodenal diseases. Molecular Microbiology, 1993, 9, 645-652.	1.2	123
543	Cell vacuolization induced byHelicobacter pylori: Inhibition by bafilomycins A1, B1, C1 and D. FEMS Microbiology Letters, 1993, 113, 155-159.	0.7	28
544	Development and Clinical Results with an Acellular Vaccine Containing Genetically Detoxified Pertussis Toxin. Biologicals, 1993, 21, 2-3.	0.5	0
545	Formaldehyde-treatment of Proteins Constrains Recognition by T Cells In Vitro But Not In Vivo. Biologicals, 1993, 21, 23.	0.5	1
546	Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children. Journal of Pediatrics, 1993, 123, 81-84.	0.9	31
547	Recombinant DNA vaccines: Rationale and strategy. Trends in Microbiology, 1993, 1, 73-74.	3.5	0
548	Adhesion of Bordetella pertussis to eukaryotic cells requires a time-dependent export and maturation of filamentous hemagglutinin.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9204-9208.	3.3	55
549	Inhibition of Helicobacter pylori urease by omeprazole. European Journal of Gastroenterology and Hepatology, 1993, 5, 683-686.	0.8	46
550	DNA topology affects transcriptional regulation of the pertussis toxin gene of Bordetella pertussis in Escherichia coli and in vitro. Journal of Bacteriology, 1993, 175, 4764-4771.	1.0	25
551	Growth of Helicobacter pylori in media containing cyclodextrins. Journal of Clinical Microbiology, 1993, 31, 160-162.	1.8	86
552	Priming to heat shock proteins in infants vaccinated against pertussis. Journal of Immunology, 1993, 150, 2025-32.	0.4	38
553	Cell penetration of diphtheria toxin. Reduction of the interchain disulfide bridge is the rate-limiting step of translocation in the cytosol. Journal of Biological Chemistry, 1993, 268, 1567-74.	1.6	83
554	Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2990-2994.	3.3	23
555	Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12- to 24- and 2- to 4-month-old children. Journal of Pediatrics, 1992, 120, 680-685.	0.9	49
556	Functional analysis of the pertussis toxin promoter. Research in Microbiology, 1992, 143, 671-681.	1.0	13
557	Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin. Immunobiology, 1992, 184, 230-239.	0.8	13
558	Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine, 1992, 10, 691-698.	1.7	161

#	Article	IF	Citations
559	Molecular epidemiology of nasopharyngeal corynebacteria in healthy adults from an area where diphtheria vaccination has been extensively practiced. European Journal of Epidemiology, 1992, 8, 560-567.	2.5	11
560	Micro Correspondence. Molecular Microbiology, 1992, 6, 2209-2211.	1.2	26
561	Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccinescan circumvent the need for adjuvants and	1.6	120
562	Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin. Infection and Immunity, 1992, 60, 5071-5077.	1.0	31
563	Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule. Infection and Immunity, 1992, 60, 1150-1155.	1.0	17
564	Generation of human monoclonal antibodies that confer protection against pertussis toxin. Infection and Immunity, 1992, 60, 1258-1260.	1.0	9
565	Differential response of the bvg virulence regulon of Bordetella pertussis to MgSO4 modulation. Journal of Bacteriology, 1991, 173, 7401-7404.	1.0	41
566	Towards third-generation whooping cough vaccines. Trends in Biotechnology, 1991, 9, 232-238.	4.9	16
567	Computer modelling of the NAD binding site of ADP-ribosylating toxins: active-site structure and mechanism of NAD binding. Molecular Microbiology, 1991, 5, 23-31.	1.2	75
568	Structural and genetic analysis of the bvg locus in Bordetella species. Molecular Microbiology, 1991, 5, 2481-2491.	1.2	95
569	The bvg-dependent promoters show similar behaviour in different Bordetella species and share sequence homologies. Molecular Microbiology, 1991, 5, 2493-2498.	1.2	21
570	Determination of diphtheria toxin neutralizing antibody titers with a cell protein synthesis inhibition assay. Medical Microbiology and Immunology, 1991, 180, 29-35.	2.6	5
571	Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis. Infection and Immunity, 1991, 59, 3768-3773.	1.0	55
572	Properties of the B oligomer of pertussis toxin. Infection and Immunity, 1991, 59, 4732-4734.	1.0	47
573	Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infection and Immunity, 1991, 59, 625-630.	1.0	83
574	Identification of subregions of Bordetella pertussis filamentous hemagglutinin that stimulate human T-cell responses. Infection and Immunity, 1991, 59, 3313-3315.	1.0	16
575	Further analysis of the sequence of the S1 subunit of pertussis toxin. Infection and Immunity, 1991, 59, 1177-1179.	1.0	1
576	Sequential activation and environmental regulation of virulence genes in Bordetella pertussis. EMBO Journal, 1991, 10, 3971-5.	3.5	60

#	Article	IF	Citations
577	Tyrosine 65 is photolabeled by 8-azidoadenine and 8-azidoadenosine at the NAD binding site of diphtheria toxin. Journal of Biological Chemistry, 1991, 266, 2494-8.	1.6	23
578	Positive transcriptional feedback at the bvg locus controls expression of virulence factors in Bordetella pertussis.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 6753-6757.	3.3	136
579	Genetic characterization of Bordetella pertussis filamentous haemagglutinin: a protein processed from an unusually large precursor. Molecular Microbiology, 1990, 4, 787-800.	1.2	122
580	DNA sequence homology betweenattB-related sites ofCorynebacterium diphtheriae, Corynebacterium ulcerans, Corynebacterium glutamicum, and theattP side of ÃŽÂ³-Cornephage. FEMS Microbiology Letters, 1990, 66, 299-301.	0.7	6
581	Histidine-21 is involved in diphtheria toxin NAD+ binding. Toxicon, 1990, 28, 631-635.	0.8	21
582	Haemophilus influenzae infections and whooping cough. Lancet, The, 1990, 335, 1324-1329.	6.3	46
583	Identification of a 35-kilodalton Mycobacterium tuberculosis protein containing B- and T-cell epitopes. Infection and Immunity, 1990, 58, 245-251.	1.0	15
584	Biochemical and biological activities of recombinant S1 subunit of pertussis toxin. Infection and Immunity, 1990, 58, 999-1003.	1.0	10
585	The subunit S1 is important for pertussis toxin secretion. Journal of Biological Chemistry, 1990, 265, 17759-63.	1.6	49
586	Pertussis toxin promoter sequences involved in modulation. Journal of Bacteriology, 1989, 171, 4026-4030.	1.0	57
587	Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map.. Journal of Experimental Medicine, 1989, 169, 1519-1532.	4.2	70
588	[28] Selective immunotoxins prepared with mutant diphtheria toxins coupled to monoclonal antibodies. Methods in Enzymology, 1989, 178, 404-422.	0.4	3
589	Genetics of pertussis toxin. Molecular Microbiology, 1989, 3, 119-124.	1.2	39
590	Families of bacterial signal-transducing proteins. Molecular Microbiology, 1989, 3, 1661-1667.	1.2	187
591	Phase variants of Bordetella bronchiseptica arise by spontaneous deletions in the vir locus. Molecular Microbiology, 1989, 3, 1719-1728.	1.2	90
592	Studies of the antigenic structure of two cross-reacting proteins, pertussis and cholera toxins, using synthetic peptides. Molecular Immunology, 1989, 26, 95-100.	1.0	15
593	Mutants of pertussis toxin suitable for vaccine development. Science, 1989, 246, 497-500.	6.0	341
594	Sequences required for expression of Bordetella pertussis virulence factors share homology with prokaryotic signal transduction proteins. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 6671-6675.	3.3	306

#	Article	IF	Citations
595	Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 2637-2641.	3.3	368
596	Photolabeling of Glu-129 of the S-1 subunit of pertussis toxin with NAD. Infection and Immunity, 1989, 57, 3549-3554.	1.0	61
597	Histidine 21 is at the NAD+ binding site of diphtheria toxin. Journal of Biological Chemistry, 1989, 264, 12385-8.	1.6	47
598	Cloning of a novel pilin-like gene from Bordetella pertussis: homology to the fim2 gene. Molecular Microbiology, 1988, 2, 539-543.	1.2	37
599	Monoclonal antibodies against pertussis toxin subunits. FEMS Microbiology Letters, 1988, 51, 7-11.	0.7	14
600	Molecular Epidemiology of the 1984â€"1986 Outbreak of Diphtheria in Sweden. New England Journal of Medicine, 1988, 318, 12-14.	13.9	110
601	Cytoskeletal alterations as a parameter for assessment of toxicity. Xenobiotica, 1988, 18, 715-724.	0.5	12
602	Dissecting human T cell responses against Bordetella species.. Journal of Experimental Medicine, 1988, 168, 1351-1362.	4.2	87
603	Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 7521-7525.	3.3	117
604	Positive regulation of pertussis toxin expression.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3913-3917.	3.3	111
605	On the membrane translocation of diphtheria toxin: at low pH the toxin induces ion channels on cells. EMBO Journal, 1988, 7, 3353-9.	3.5	22
606	A C terminus cysteine of diphtheria toxin B chain involved in immunotoxin cell penetration and cytotoxicity. Journal of Immunology, 1988, 140, 2466-71.	0.4	14
607	The nucleotide sequence of the gene coding for diphtheria toxoid CRM176. Nucleic Acids Research, 1987, 15, 5897-5897.	6.5	5
608	Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. Journal of Bacteriology, 1987, 169, 2847-2853.	1.0	239
609	High-level expression of a proteolytically sensitive diphtheria toxin fragment in Escherichia coli. Journal of Bacteriology, 1987, 169, 5140-5151.	1.0	55
610	Diphtheria toxin and its mutantcrm197 differ in their interaction with lipids. FEBS Letters, 1987, 215, 73-78.	1.3	33
611	Conformational changes in diphtheria toxoids. FEBS Letters, 1987, 218, 271-276.	1.3	32
612	DNA element of Corynebacterium diphtheriae with properties of an insertion sequence and usefulness for epidemiological studies. Journal of Bacteriology, 1987, 169, 308-312.	1.0	41

#	Article	IF	Citations
613	Promoter of the pertussis toxin operon and production of pertussis toxin. Journal of Bacteriology, 1987, 169, 2843-2846.	1.0	63
614	Evolutionary relationships in the genus Bordetella. Molecular Microbiology, 1987, 1, 301-308.	1.2	92
615	Lipid interaction of diphtheria toxin and mutants with altered fragment B. 1. Liposome aggregation and fusion. FEBS Journal, 1987, 169, 629-635.	0.2	38
616	Lipid interaction of diphtheria toxin and mutants with altered fragment B. 2. Hydrophobic photolabelling and cell intoxication. FEBS Journal, 1987, 169, 637-644.	0.2	68
617	Expression and immunological properties of the five subunits of pertussis toxin. Infection and Immunity, 1987, 55, 963-967.	1.0	124
618	Expression of the S-1 catalytic subunit of pertussis toxin in Escherichia coli. Infection and Immunity, 1987, 55, 1321-1323.	1.0	32
619	Hydrophobic photolabelling of pertussis toxin subunits interacting with lipids. FEBS Letters, 1986, 194, 301-304.	1.3	26
620	Detection of homology to the beta bacteriophage integration site in a wide variety of Corynebacterium spp. Journal of Bacteriology, 1986, 168, 103-108.	1.0	19
621	Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 4631-4635.	3.3	358
622	Production of Large Quantities of Diphtheria Toxoid CRM45. Bio/technology, 1985, 3, 161-163.	1.9	3
623	Detection and physical map of a omega tox+-related defective prophage in Corynebacterium diphtheriae Belfanti 1030(-)tox-. Journal of Virology, 1985, 54, 194-198.	1.5	6
624	The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Research, 1984, 12, 4063-4069.	6.5	247
625	Physical map of the chromosomal region of Corynebacterium diphtheriae containing corynephage attachment sites attB1 and attB2. Journal of Bacteriology, 1984, 158, 325-330.	1.0	26
626	IgA-dependent cell-mediated activity against enteropathogenic bacteria: distribution, specificity, and characterization of the effector cells. Journal of Immunology, 1984, 133, 988-92.	0.4	55
627	Rapid purification of diphtheria toxin by phenyl sepharose and DEAE-cellulose chromatography. Journal of Chromatography A, 1983, 268, 543-548.	1.8	28
628	The complete nucleotide sequence of the gene coding for diphtheria toxin in the corynephage omega (tox+) genome. Nucleic Acids Research, 1983, 11, 6589-6595.	6.5	115
629	Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197. Applied and Environmental Microbiology, 1983, 46, 560-564.	1.4	52
630	Integration of corynebacteriophages beta tox+, omega tox+, and gamma tox- into two attachment sites on the Corynebacterium diphtheriae chromosome. Journal of Bacteriology, 1983, 153, 1202-1210.	1.0	55

#	Article	IF	Citations
631	Restriction endonuclease map of corynebacteriophage omega ctox+ isolated from the Park-Williams no. 8 strain of Corynebacterium diphtheriae. Journal of Virology, 1983, 45, 524-530.	1.5	38
632	Restriction endonuclease map of the nontoxigenic corynephage gamma c and its relationship to the toxigenic corynephage beta c. Journal of Virology, 1982, 42, 510-518.	1.5	40
633	Competitive enzyme immunoassay for human chorionic somatomammotropin using the avidin-biotin system. Analytical Biochemistry, 1981, 118, 168-172.	1.1	19
634	Restriction map of corynebacteriophages beta c and beta vir and physical localization of the diphtheria tox operon. Journal of Bacteriology, 1981, 148, 124-130.	1.0	43
635	Meningococcal Vaccines: A Technological Revolution. Frontiers for Young Minds, 0, 8, .	0.8	0
636	Antimicrobial Resistance: A Tale of Nasty Enemies and Powerful Weapons. Frontiers for Young Minds, 0, 8, .	0.8	1